While they are all made from the same ingredient, they differ in terms of FDA-approved uses and other important metrics, including dosing
Broad compounding of semaglutide because of the shortage is no longer permittedthe FDA resolved the shortage on February 21, 2025, and the grace periods ended by May 22, 2025
Transitioning Between Semaglutide and Tirzepatide Switching between these two medications is not as simple as stopping one and starting the other on the same day
In practice, this means: No persistent nausea or vomiting for at least 7 consecutive days at the end of the current phase No ongoing diarrhea or significant GI discomfort that impacts daily functioning You are in week 4 or later at the current dose level (the 4-week minimum is absolute) If any of those conditions are not met at week 4, you are not ready to escalate
Hydration Levels: Dehydration can sometimes be mistaken for hunger, potentially masking the effects of the medication
The eligible population was recently expanded when the American Society for Metabolic and Bariatric Surgery updated its clinical guidelines for metabolic and bariatric surgery in 2022